NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined 2%. CS Medica gave an update on its IPO of the CANNORDIC subsidiary in Germany, Initiator Pharma finalized a small buyback program, and Saniona converted convertibles into shares for MSEK 2. Moreover, two stocks focusing on the immune system rose nearly 200%.
Only 9 of the 22 Danish biotech companies had a positive share price development in the past week and 12 companies have had a positive share price performance year-to-date Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. Five Danish healthcare stocks with +100% YTD return.
Danish company news
No news the past week
No news the past week
No news the past week
No news the past week
CS MEDICA A/S Update from CEO: Progress on CANNORDIC IPO, Share Distribution & Upcoming Market Analysis (Link)
No news the past week
No news the past week
No news the past week
The Board of Directors of ExpreS2ion Biotech Holding AB (publ) has resolved on the record date for the reverse share split (Link)
Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide (Link)
No news the past week
No news the past week
Finalization of share buyback program in Initiator Pharma (Link)
No news the past week
No news the past week
Fenja Capital II A/S requests conversion of outstanding convertibles for a total nominal amount of SEK 2 million (Link)
No news the past week
No news the past week
No news the past week
No news the past week
Y-mAbs Therapeutics is to announce its Q3 2024 results on November 8.
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a negative return of 2.3%. It was a week with very few company-related news. CS Medica gave an update on its IPO of CANNORDIC in Germany. Initiator Pharma finalized a small buyback program, a board member resigned at Fluoguide, and Saniona converted convertibles into shares for around MSEK 2 at a conversion price of SEK 3.09 per share.
Gubra continues to be the best-performing stock year-to-date with a return of 238%. Pila Pharma, Zealand Pharma and Y-mAbs Therapeutic have also generated returns of over 100% in 2024. Cessatech is at 95%.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) declined 2% to 65,08. The healthcare index has had a strong performance since the beginning of October last year with an increase of around 15%. The index has performed significantly better than the KPNGX index. However, the index is still behind the large-cap indices. With large caps having outperformed massively in 2024, the performance of the KPHC, with many small and micro caps, is quite good.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
Circio Holding (187%) expertise is in targeted immunotherapy used in the treatment of cancer patients. The company’s operations consist of research and development and the pharmaceuticals are currently sold under separate brands. Several partnerships in the market have been entered to strengthen cooperation in the development of new immunotherapy.
Active Biotech (171%) develops drugs in disease areas such as cancer and inflammatory diseases where the immune system plays a crucial role. The company’s project portfolio contains both small orally active immunomodulatory molecules and antibody-based immunotherapy. The company focuses on projects in specialist indications in disease areas such as hematological cancer, inflammatory eye diseases, and solid tumors.
Nattaro Labs (85%) is a Swedish research and development company focused on the control and elimination of bed bugs. The company is an international bedbug specialist with global collaborations in the remediation industry. The product range includes development and solutions to prevent and control bed bugs. The company raised MSEK 5.1 at a 110% premium.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
